AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 311.3 USD | +11.82% |
|
+15.56% | +8.08% |
| 03/05 | News Highlights : Top Company News of the Day - Friday at 5 PM ET | DJ |
| 03/05 | News Highlights : Top Company News of the Day - Friday at 7 PM ET | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
311.3
USD
Average target price
311.3
USD
Spread / Average Target
-0.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.08% | 149B | |
| +26.08% | 681B | |
| +21.85% | 556B | |
| -4.77% | 361B | |
| +16.97% | 325B | |
| +5.69% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -3.40% | 157B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen : AstraZeneca Say Study on Severe Asthma Drug Candidate Did Not Meet Primary Endpoint
